Preconception Mycoplasma genitalium Seropositivity and Risk of Impaired Fecundity

A secondary analysis of the EAGeR trial found that while preconception *Mycoplasma genitalium* seropositivity alone was not significantly associated with impaired fecundity, co-seropositivity with *Chlamydia trachomatis* was linked to a reduced likelihood of live birth.

The Gist

The Big Picture: A "Reproductive Health Check-Up"

Imagine your body's reproductive system as a highly efficient factory designed to build a baby. For this factory to run smoothly, the machinery (your fallopian tubes and uterus) needs to be clean and free of damage.

This study looked at a group of women who were already trying to have babies and had proven they could get pregnant (they had done it before), but they had also experienced a miscarriage in the past. The researchers wanted to know: Do hidden infections from the past act like "rust" on the factory machinery, making it harder to build a baby or keep it safe?

Specifically, they were investigating a bacteria called Mycoplasma genitalium (MG). Think of MG as a "silent saboteur." Unlike some infections that scream for attention with pain or discharge, MG often hides quietly, leaving behind invisible scars that might mess with fertility later on.

The Investigation: The "Detective Work"

The researchers didn't just ask the women, "Do you have an infection?" (because they often don't know). Instead, they acted like forensic detectives.

They took blood samples stored from a previous study (the EAGeR trial) and looked for antibodies.

• The Analogy: Think of antibodies as "wanted posters" or "mugshots" left in the blood. Even if the bacteria is gone, the body keeps these posters as proof that a break-in happened in the past.
• They checked for MG, but they also checked for other common "thieves" like Chlamydia (CT), Trichomonas (TV), and Gonorrhea (NG).

The Findings: What the Rust Did (and Didn't Do)

Here is what the detectives found, broken down simply:

1. The "Silent Saboteur" (MG Alone)

The Finding: Having a past infection with MG by itself didn't seem to stop the factory from working.
The Analogy: Imagine a factory that had a minor dust storm (MG) years ago. The study found that having that dust storm in the past didn't necessarily mean the machines were broken today. The women with MG alone were just as likely to have a baby as women with no infections at all.

• Note: There was a tiny hint that it might slow things down a little (taking a bit longer to get pregnant), but it wasn't a strong enough signal to say for sure.

2. The "Double Trouble" (MG + Chlamydia)

The Finding: This is the most important part. When a woman had both MG and Chlamydia in her past, the factory struggled significantly.
The Analogy: Imagine the factory had a dust storm (MG) and a flood (Chlamydia) at the same time. The combination was much worse than either disaster alone.

• Women who were "co-seropositive" (had evidence of both bugs) were less likely to have a live birth. It's as if the double damage made the machinery too fragile to finish the job of growing a baby to term.

3. The "Odd Couple" (MG + Trichomonas/Gonorrhea)

The Finding: Interestingly, when MG was paired with other bugs like Trichomonas or Gonorrhea, the results were actually better than expected.
The Analogy: It's like finding a broken gear (MG) but realizing the rest of the machine is surprisingly sturdy. Women with this specific mix didn't seem to have the same bad outcomes as the "Double Trouble" group.

Why This Matters: The "Prevention" Lesson

The study concludes that while MG is a known troublemaker for pelvic health, it's the "team-up" with Chlamydia that really hurts fertility.

• The Takeaway: Think of your reproductive health like a house. If you have a leaky roof (Chlamydia) and a termite problem (MG) happening at the same time, the house is in serious danger of collapsing (miscarriage or infertility). Fixing just one might not be enough; you need to know if both are present to fully protect the home.

The Bottom Line for Everyone

1. MG is sneaky: It stays in the body's memory (antibodies) long after the infection is gone.
2. Solo MG isn't the main villain: In this group of women, MG alone didn't stop them from having babies.
3. The Combo is the danger: If you have a history of both MG and Chlamydia, your chances of a successful pregnancy might be lower.
4. Screening is key: Since MG is often asymptomatic (no symptoms), we might be missing the "rust" until it causes a problem. Knowing your status helps doctors protect your "factory" better.

In short: This study tells us that while one bad bug might not ruin the party, a party crasher duo (MG + Chlamydia) can definitely spoil the celebration of bringing a new life into the world.

Technical Summary

1. Problem Statement

Mycoplasma genitalium (MG) is an emerging sexually transmitted infection (STI) associated with pelvic inflammatory disease (PID) and tubal factor infertility. However, its specific relationship with impaired fecundity (the ability to conceive) and other pregnancy outcomes (such as pregnancy loss and live birth rates) remains unclear.

• Knowledge Gaps: Existing literature is limited, often conducted in infertility clinics, lacks assessment of early pregnancy loss, and insufficiently adjusts for confounders.
• Co-infection Complexity: A significant proportion of MG-infected women are co-infected with Chlamydia trachomatis (CT). It is unknown whether the reproductive risks are driven by MG alone or exacerbated by co-seropositivity with CT or other STIs (Trichomonas vaginalis and Neisseria gonorrhoeae).
• Objective: To assess whether preconception MG seropositivity is associated with indicators of impaired fecundity and adverse pregnancy outcomes, and to determine if co-seropositivity with CT modifies these risks.

2. Methodology

Study Design & Population:

• Source: Secondary analysis of the EAGeR trial (Effects of Aspirin in Gestation and Reproduction), a prospective preconception cohort.
• Participants: 1,228 healthy women (aged 18–40) with proven fecundity and a history of 1–2 prior pregnancy losses, actively attempting conception.
• Exclusions: 16 participants with inconclusive MG serological tests were excluded from primary analyses to prevent exposure misclassification. The final analytical sample was 1,146 participants.

Exposure Assessment:

• Serology: Preconception serum samples were tested for IgG antibodies against MG using a Western blot assay (MG075F1 recombinant protein) designed to minimize cross-reactivity with M. pneumoniae.
• Co-infection: Participants were also tested for CT, Trichomonas vaginalis (TV), and Neisseria gonorrhoeae (NG) using specific serologic assays.
• Grouping: Participants were categorized into:
  1. Seronegative for all STIs (Reference).
  2. MG mono-seropositive.
  3. MG co-seropositive with CT.
  4. MG co-seropositive with TV and/or NG.
  5. Seronegative for MG but positive for other STIs.

Outcomes:

• Primary: Live birth and pregnancy loss.
• Secondary: Fecundability (time-to-pregnancy), hypertensive disorders of pregnancy (HDP), preterm birth, and time-to-delivery.

Statistical Analysis:

• Imputation: Multiple imputation with chained equations (10 datasets) was used for missing covariate data.
• Modeling:
  • Fecundability: Discrete Cox proportional hazards models (Fecundability Odds Ratio - FOR).
  • Live Birth/Pregnancy Loss: Log-binomial and quasi-Poisson models (Relative Risk - RR).
  • Bias Mitigation: Inverse Probability Weighting (IPW) was applied to outcomes conditional on conception or pregnancy progression to address selection bias (e.g., conditioning on $\beta$-hCG positivity).
  • Co-infection Analysis: Due to reduced sample sizes in stratified groups, Propensity Score (PS) weighting (via gradient boosted logistic regression) was used to balance confounders across exposure groups.
• Sensitivity: E-values were calculated to assess the robustness of findings against unmeasured confounding.

3. Key Results

Prevalence:

• MG Seropositivity: 17.1% (n=210) of the cohort.
• Co-infection: Among MG-positive women, 27.6% (n=58) were co-seropositive with CT.
• Demographics: MG seropositive women were slightly older, had higher BMI, lower education/income, and higher rates of smoking and alcohol use compared to seronegative women.

Primary Findings (MG Seropositivity vs. Seronegative):

• Overall MG Seropositivity: Not significantly associated with live birth, pregnancy loss, or fecundability after adjustment.
  • Trend: Reduced fecundability (FOR$_{adj}$: 0.87, 95% CI: 0.70–1.08) and reduced live birth (RR$_{adj}$: 0.94, 95% CI: 0.79–1.11), though confidence intervals crossed the null.
• MG-CT Co-seropositivity: This group showed a statistically significant reduction in live birth compared to the seronegative reference group.
  • Live Birth: RR$_{PS-weighted}$: 0.82 (95% CI: 0.70–0.96).
  • Pregnancy Loss: Trend toward increased risk (RR$_{PS-weighted}$: 1.20, 95% CI: 0.98–1.45).
  • Fecundability: Strong trend toward reduced fecundability (FOR$_{PS-weighted}$: 0.61, 95% CI: 0.36–1.03).
• MG-Other STI Co-seropositivity: MG co-seropositivity with TV/NG was associated with a lower risk of pregnancy loss (RR$_{PS-weighted}$: 0.84) and a trend toward higher live birth rates, though these were not statistically significant for live birth.

Other STIs:

• CT Mono-seropositivity: Showed higher pregnancy loss and lower live birth rates compared to other groups, consistent with prior EAGeR analyses.
• NG Seropositivity: Small sample size (n=32) showed poor outcomes (lowest conception rate, longest time-to-pregnancy), but regression analysis was not feasible due to low power.

Sensitivity Analysis:

• E-values indicated that an unmeasured confounder would need a risk ratio of at least 1.74 to fully explain away the observed association between MG-CT co-seropositivity and reduced live birth, suggesting the finding is robust.
• Imputing the 16 excluded inconclusive cases yielded comparable results.

4. Key Contributions

1. Differentiation of Mono- vs. Co-infection: The study is one of the first to rigorously separate the effects of MG alone from MG-CT co-infection in a preconception cohort, revealing that the adverse effect on live birth is driven primarily by the co-infection.
2. Methodological Rigor: The application of IPW and Propensity Score weighting addresses critical selection biases common in preconception studies (e.g., conditioning on conception), providing more reliable estimates of fecundity and pregnancy loss than previous studies.
3. Serological Approach: Utilizing IgG seropositivity allows for the assessment of past exposure and potential long-term reproductive tract damage, rather than just active infection, which is often asymptomatic and transient.
4. Population Context: The study demonstrates that even in a "low-risk" population (women with proven fecundity and low STI burden in Utah), MG-CT co-seropositivity poses a measurable risk to reproductive success.

5. Significance and Implications

• Clinical Relevance: The findings suggest that while prior MG exposure alone may not drastically impair fecundity, co-exposure to MG and CT significantly reduces the likelihood of a live birth. This highlights the importance of screening and treating co-infections, particularly given the rising prevalence of antibiotic-resistant MG strains.
• Public Health: The study supports the hypothesis that MG contributes to tubal factor infertility and adverse pregnancy outcomes, but its impact is potentiated by co-infection with CT.
• Future Research: The authors call for larger, more diverse studies to confirm these findings and investigate the biological mechanisms (e.g., chronic inflammation, tissue damage) linking dual seropositivity to impaired fecundity.
• Limitations: The study is limited by its specific demographic (mostly White, higher socioeconomic status, Utah-based) and the use of serology (which indicates past exposure but not necessarily active infection at the time of conception). However, the robust statistical adjustments mitigate many of these concerns.

Conclusion: Preconception co-seropositivity for Mycoplasma genitalium and Chlamydia trachomatis is associated with a reduced likelihood of live birth, suggesting a synergistic negative effect on fecundity that warrants further clinical investigation and potential screening strategies.